'%20d='m0%200%2016%2011h61%2061%2061%2061%2060L47%2037h61%2061%2060%2061L16%2063h61%2061%2061%2061%2060L47%2089h61%2061%2060%2061L16%20115h61%2061%2061%2061%2060L47%20141h61%2061%2060%2061L16%20166h61%2061%2061%2061%2060L47%20192h61%2061%2060%2061L16%20218h61%2061%2061%2061%2060z'/%3e%3c/svg%3e)
About
Ask any American clinic how many eggs you have left and the answer comes back as a blood test — anti-Müllerian hormone. David Seifer’s work on reproductive aging at Yale is part of how that number got into the standard workup, and the association earned his group a Thomas Alva Edison Patent Award in 2011. He still sees the clinical version of the same question every day: how much time a particular patient actually has, and whether freezing eggs, using donor eggs or moving to a gestational carrier is the right answer this cycle rather than next year.
He also decides who gets trained to answer it. As director of Yale’s reproductive endocrinology and infertility fellowship program, Seifer runs the curriculum that turns obstetrics and gynecology residents into REI specialists, which means the fellows rotating through Yale Medicine Fertility Center are his responsibility. In 2017-2018 he served as president of the Society for Assisted Reproductive Technology, the body that sets the clinic-level safety and reporting standards behind the success data published for this center.
He describes his own role as a liaison — matching a patient to the medical option that fits the medicine and the patient’s own values, rather than pushing one pathway. That framing shows in his panel, which spans elective egg freezing, donor egg and donor embryo work, surrogacy, and the 42-and-over consultations most programs hand back to a coordinator’s script. His published research in JAMA and Fertility & Sterility covers cumulative live birth using a woman’s own eggs after 42, the effect of PGT-A on miscarriage rates, how AI might be used in the lab, and the racial and ethnic gaps in access to and outcomes of assisted reproduction; he has held seats on an NICHD reproductive, male and gynecologic study group and on an FDA obstetrics and gynecology device advisory committee, and he is a co-editor-in-chief of Reproductive Biology and Endocrinology. His Yale profile records 25 consecutive years in the Castle Connolly America’s Top Doctors guide, Connecticut Magazine top-doctor listings from 2021 forward, ASRM Star Physician recognition, a 2011 New Jersey Inventors Hall of Fame inventor-of-the-year award, and a 2021-2022 Ferring Pharmaceutical fund for work on racial equity in reproductive medicine and maternal-fetal health.
Clinical Expertise
Ovarian reserve assessment is his home ground: interpreting AMH and antral follicle count together, and telling a patient what her number does and does not predict about a single cycle.
Egg freezing, both elective and before gonadotoxic treatment, including the counseling about how many eggs a given retrieval is likely to yield at a given age.
Donor egg, donor embryo and gestational carrier cycles, where the medical decision is inseparable from legal and ethical ones.
Aging and infertility over 40, including his published work on cumulative live birth with a patient’s own eggs at that age.
Preimplantation genetic testing and miscarriage, specifically whether PGT-A changes loss rates.
Why Choose Dr. Seifer
He wrote part of the rulebook. A SART presidency in 2017-2018 means he oversaw the standards that clinics report against, including how outcomes get counted and published.
He trains this field’s specialists. Fellows come through his program, so the medicine you are offered has been taught out loud rather than picked up.
A named patent milestone. The 2011 Edison Patent Award attaches to the AMH test line his research supported — a specific claim rather than a general reputation.
Long recognition record. Twenty-five consecutive Castle Connolly listings, per his Yale profile, is duration rather than a single year’s marketing.
He works on unequal outcomes. His disparity research and the 2021-2022 Ferring equity award both concern who gets access to ART, which matters if you are weighing a program’s willingness to discuss your real odds.
Professional Affiliations
Society for Assisted Reproductive Technology, president 2017-2018. American Society for Reproductive Medicine, Star Physician recognition recorded 2016-2025. American Board of Obstetrics and Gynecology, certified in obstetrics and gynecology (1989, renewed 2020) and in reproductive endocrinology and infertility (1994, renewed 2020). Co-editor-in-chief, Reproductive Biology and Endocrinology. Former member, NICHD reproductive, male and gynecologic sciences study group, and of an FDA obstetrics and gynecology device panel. He took his MD at the University of Illinois at Chicago in 1981 and completed his REI fellowship at Yale in 1991, and has practiced in reproductive medicine for over four decades.
Suitable For
- Women considering egg freezing who want the reserve numbers interpreted rather than just ordered
- Patients with diminished ovarian reserve, including those told their count ends the conversation
- Any family built on donor eggs, donor embryos or a gestational carrier, where planning and consent carry as much weight as the stimulation protocol
- Second opinions on long or complicated infertility, particularly over 40
- Patients who want their values in the plan — his stated method is matching options to what a patient actually wants, not to a default pathway